Who qualifies for stiripentol?
Stiripentol is FDA-approved for Dravet syndrome patients aged 2 years and older who are also taking clobazam.[1] Ideal candidates have refractory seizures inadequately controlled by standard treatments, as stiripentol acts as an adjunctive anticonvulsant.
What is Dravet syndrome, and why stiripentol?
Dravet syndrome is a rare, severe genetic epilepsy starting in infancy, often due to SCN1A mutations, with frequent, drug-resistant seizures including prolonged convulsions.[1][2] Stiripentol targets this by inhibiting GABA breakdown and modulating voltage-gated sodium channels, reducing seizure frequency by at least 50% in about half of patients in trials.[1]
Key eligibility criteria from clinical guidelines
- Age and diagnosis: Confirmed Dravet syndrome diagnosis via genetic testing or clinical history (e.g., seizure onset before 1 year, multiple seizure types, developmental delays).[1][3]
- Prior treatment failure: Seizures persist despite two or more anti-seizure medications.[1]
- Concomitant therapy: Must be on clobazam; stiripentol boosts its levels for synergy.[1]
- Weight and monitoring: Body weight over 11 kg for dosing; requires liver function tests due to metabolism effects.[3]
Patients without clobazam or outside Dravet are not ideal, as approval is specific.
What do trial data show about responders?
In pivotal studies (e.g., STICLO trials), responders had fewer drop attacks and generalized clonic-tonic seizures.[1][2] Best outcomes in children 3+ years with baseline seizure rates over 15/month. Non-responders often had atypical presentations or comorbidities.
Common exclusions and risks for candidates
Avoid in patients with hepatic impairment, CYP2C19 poor metabolizers (risk of high clobazam levels), or allergies to components.[3] Monitor for sedation, ataxia, and appetite loss; not for absence or myoclonic seizures alone.
Alternatives if not a fit
Fenfluramine or cannabidiol suit similar Dravet patients but differ in mechanisms—fenfluramine activates serotonin receptors, cannabidiol via multiple pathways.[2] Genetic testing guides switches.
[1]: FDA Label for Diacomit (stiripentol)
[2]: Epilepsia: Stiripentol in Dravet syndrome review
[3]: Drugs.com: Stiripentol prescribing information